Inhibition of the RNA translation factor, eIF4E, as a novel treatment strategy in Ewing Sarcoma
Inhibition of the RNA translation factor, eIF4E, as a novel treatment strategy in Ewing Sarcoma
Dr. John Prensner, M.D., Ph.D. – The Regents of the University of Michigan, Ann Arbor, MI
GLUL as a novel therapeutic target in pediatric T-ALL
GLUL as a novel therapeutic target in pediatric T-ALL
Dr. Daniel Herranz, Ph.D. – Rutgers Biomedical and Health Sciences (Rutgers Health), New Brunswick, NJ
Dissecting CBFA2T3-GLIS2 Fusion-Driven Leukemogenesis and Therapeutic Resistance
Dissecting CBFA2T3-GLIS2 Fusion-Driven Leukemogenesis and Therapeutic Resistance
Dr. Brandon Hadland, M.D. – Fred Hutchinson Cancer Center, Seattle, WA
Identify Genetic Drivers Metastasis Using an Established Zebrafish Model of High-Risk Neuroblastoma
Identify Genetic Drivers Metastasis Using an Established Zebrafish Model of High-Risk Neuroblastoma
Dr. Nicole Anderson, Ph.D. – University of Mississippi Medical Center, Jackson, MS
Uncovering the role of chromosome 21 in Down syndrome-associated leukemias
Uncovering the role of chromosome 21 in Down syndrome-associated leukemias
Dr. Jason Sheltzer, Ph.D. – Yale University, New Haven, CT
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
Dr. Jamie Anastas, Ph.D. – Baylor College of Medicine, Houston, TX
The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
Dr. lannis Aifantis, Ph.D. – New York University Grossman School of Medicine, New York, NY
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
Dr. Norihiro Watanabe, Ph.D. – Baylor College of Medicine
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Dr. John Prensner, M.D., Ph.D. – University of Michigan Medical Center (Michigan Medicine), Ann Arbor, MI
Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis
Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis
Dr. Yanxin Pei, M.D. – Children's Research Institute (CNMC), Washington, D.C.
Validating PRL2 as a New Therapeutic Target in T-ALL
Validating PRL2 as a New Therapeutic Target in T-ALL
Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
Dr. William Carroll, M.D. – New York University Grossman School of Medicine, New York, NY